{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T21:40:45Z","timestamp":1782337245391,"version":"3.54.5"},"reference-count":91,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.critrevonc.2023.104085","type":"journal-article","created":{"date-parts":[[2023,8,2]],"date-time":"2023-08-02T03:34:40Z","timestamp":1690947280000},"page":"104085","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Combating relapsed and refractory Mantle cell lymphoma with novel therapeutic armamentarium: Recent advances and clinical prospects"],"prefix":"10.1016","volume":"190","author":[{"given":"Neha R.","family":"Raghani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Disha D.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tithi S.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehul R.","family":"Chorawala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakesh B.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7_Supplement","key":"10.1016\/j.critrevonc.2023.104085_bib1","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2023-6208","article-title":"Abstract 6208: targeting DNA polymerase theta and ATM leads to synergistic killing of mantle cell lymphoma cells","volume":"83","author":"Abeykoon","year":"2023","journal-title":"Cancer Res."},{"issue":"10254","key":"10.1016\/j.critrevonc.2023.104085_bib2","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.critrevonc.2023.104085_bib3","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/bjh.15552","article-title":"An open-label phase 2 trial of entospletinib in indolent non-Hodgkin lymphoma and mantle cell lymphoma","volume":"184","author":"Andorsky","year":"2019","journal-title":"Br. J. Haematol."},{"issue":"4","key":"10.1016\/j.critrevonc.2023.104085_bib4","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1172\/JCI129206","article-title":"Immunotherapy of lymphomas","volume":"130","author":"Ansell","year":"2020","journal-title":"J. Clin. Invest"},{"issue":"2","key":"10.1016\/j.critrevonc.2023.104085_bib5","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1111\/bjh.15025","article-title":"Prospective subgroup analyses of the randomized MCL-002 (SPRINT) study: lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma","volume":"180","author":"Arcaini","year":"2018","journal-title":"Br. J. Haematol."},{"issue":"6","key":"10.1016\/j.critrevonc.2023.104085_bib6","first-page":"368","article-title":"Staging non-Hodgkin lymphoma","volume":"55","author":"Armitage","year":"2005","journal-title":"CA Cancer J. Clin."},{"issue":"26","key":"10.1016\/j.critrevonc.2023.104085_bib7","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMra2202672","article-title":"Mantle-cell lymphoma","volume":"386","author":"Armitage","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"92","key":"10.1016\/j.critrevonc.2023.104085_bib8","first-page":"101","article-title":"Implementation of biomarker-driven cancer therapy: existing tools and remaining gaps","volume":"17","author":"Bailey","year":"2014","journal-title":"Discov. Med"},{"issue":"45","key":"10.1016\/j.critrevonc.2023.104085_bib9","doi-asserted-by":"crossref","first-page":"18250","DOI":"10.1073\/pnas.1314608110","article-title":"Landscape of somatic mutations and clonal evolution in mantle cell lymphoma","volume":"110","author":"Be\u00e0","year":"2013","journal-title":"Proc. Natl. Acad. Sci. Usa."},{"issue":"3","key":"10.1016\/j.critrevonc.2023.104085_bib10","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1002\/hon.2197","article-title":"Zevalin and BEAM (Z-BEAM) versus rituximab and BEAM (R-BEAM) conditioning chemotherapy prior to autologous stem cell transplantation in patients with mantle cell lymphoma","volume":"34","author":"Berger","year":"2016","journal-title":"Hematol. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2023.104085_bib11","doi-asserted-by":"crossref","first-page":"e170","DOI":"10.1016\/S2352-3026(18)30030-9","article-title":"Voxtalisib (XL765) in patients with relapsed or refractory non-Hodgkin lymphoma or chronic lymphocytic leukaemia: an open-label, phase 2 trial","volume":"5","author":"Brown","year":"2018","journal-title":"Lancet Haematol."},{"issue":"6","key":"10.1016\/j.critrevonc.2023.104085_bib12","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1002\/ajh.21406","article-title":"Role and prognostic significance of the Ki-67 index in non-Hodgkin's lymphoma","volume":"84","author":"Broyde","year":"2009","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.critrevonc.2023.104085_bib13","first-page":"239","article-title":"Discovery and Development of Non-Covalent, Reversible Bruton\u2019s Tyrosine Kinase Inhibitor Fenebrutinib (GDC-0853)","volume":"Vol. 1332","author":"Crawford","year":"2019"},{"issue":"20","key":"10.1016\/j.critrevonc.2023.104085_bib14","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.2174\/1568026622666220801101706","article-title":"Next-generation Bruton\u2019s Tyrosine Kinase (BTK) Inhibitors Potentially Targeting BTK C481S Mutation- Recent Developments and Perspectives","volume":"22","author":"Das","year":"2022","journal-title":"Curr. Top. Med. Chem."},{"issue":"1","key":"10.1016\/j.critrevonc.2023.104085_bib15","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1016\/S2352-3026(18)30196-0","article-title":"Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1-1b study","volume":"6","author":"Davids","year":"2019","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.critrevonc.2023.104085_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2020.102082","article-title":"Basket trials: From tumour gnostic to tumour agnostic drug development","volume":"90","author":"Dittrich","year":"2020","journal-title":"Cancer Treat. Rev."},{"issue":"suppl_4","key":"10.1016\/j.critrevonc.2023.104085_bib17","doi-asserted-by":"crossref","first-page":"iv62","DOI":"10.1093\/annonc\/mdx223","article-title":"Newly diagnosed and relapsed mantle cell lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Dreyling","year":"2017","journal-title":"Ann. Oncol."},{"issue":"Supplement_1","key":"10.1016\/j.critrevonc.2023.104085_bib18","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-127863","article-title":"Triangle: autologous transplantation after a rituximab\/ibrutinib\/ara-c containing induction in generalized mantle cell lymphoma - a Randomized European MCL network trial","volume":"134","author":"Dreyling","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2023.104085_bib19","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.semcancer.2020.07.005","article-title":"Targeting p53 for the treatment of cancer","volume":"79","author":"Duffy","year":"2022","journal-title":"Semin Cancer Biol."},{"issue":"17","key":"10.1016\/j.critrevonc.2023.104085_bib20","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1182\/blood-2017-04-779736","article-title":"TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy","volume":"130","author":"Eskelund","year":"2017","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.critrevonc.2023.104085_bib21","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1158\/1078-0432.CCR-15-0624","article-title":"A phase I\/II multicenter, open-label study of the oral histone deacetylase inhibitor abexinostat in relapsed\/refractory lymphoma","volume":"22","author":"Evens","year":"2016","journal-title":"Clin. Cancer Res"},{"issue":"7","key":"10.1016\/j.critrevonc.2023.104085_bib22","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1073\/pnas.0510441103","article-title":"Mutation and genomic deletion status of ataxia telangiectasia mutated (ATM) and p53 confer specific gene expression profiles in mantle cell lymphoma","volume":"103","author":"Greiner","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"6","key":"10.1016\/j.critrevonc.2023.104085_bib23","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1080\/00313020500370192","article-title":"The epidemiology of non-Hodgkin lymphoma","volume":"37","author":"Grulich","year":"2005","journal-title":"Pathology"},{"issue":"3","key":"10.1016\/j.critrevonc.2023.104085_bib24","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/bjh.14866","article-title":"Activity of lenalidomide in mantle cell lymphoma can be explained by NK cell-mediated cytotoxicity","volume":"179","author":"Hagner","year":"2017","journal-title":"Br. J. Haematol."},{"issue":"12","key":"10.1016\/j.critrevonc.2023.104085_bib25","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1038\/leu.2011.162","article-title":"Impact of TP53 mutation and 17p deletion in mantle cell lymphoma","volume":"25","author":"Halld\u00f3rsd\u00f3ttir","year":"2011","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.critrevonc.2023.104085_bib26","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1007\/s00277-020-03956-0","article-title":"Radioimmunotherapy for mantle cell lymphoma: 5-year follow-up of 90 patients from the international RIT registry","volume":"99","author":"Hohloch","year":"2020","journal-title":"Ann. Hematol.,"},{"key":"10.1016\/j.critrevonc.2023.104085_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2020.107720","article-title":"Current developments of targeting the p53 signaling pathway for cancer treatment","volume":"220","author":"Huang","year":"2021","journal-title":"Pharm. Ther."},{"issue":"18","key":"10.1016\/j.critrevonc.2023.104085_bib28","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1200\/JCO.20.03175","article-title":"Glofitamab, a novel, bivalent CD20-Targeting T-cell-engaging bispecific antibody, induces durable complete remissions in relapsed or refractory b-cell lymphoma: a phase I Trial","volume":"39","author":"Hutchings","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.critrevonc.2023.104085_bib29","doi-asserted-by":"crossref","first-page":"3606","DOI":"10.1182\/bloodadvances.2021006922","article-title":"Real-world evidence of brexucabtagene autoleucel for the treatment of relapsed or refractory mantle cell lymphoma","volume":"6","author":"Iacoboni","year":"2022","journal-title":"Blood Adv.,"},{"issue":"7","key":"10.1016\/j.critrevonc.2023.104085_bib30","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1080\/10428194.2017.1390233","article-title":"Randomized phase II study of a bendamustine monotherapy schedule for relapsed or refractory low-grade B-cell non-Hodgkin lymphoma or mantle cell lymphoma (RABBIT-14","volume":"59","author":"Itoh","year":"2018","journal-title":"Leuk. Lymphoma"},{"issue":"6","key":"10.1016\/j.critrevonc.2023.104085_bib31","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1111\/cas.14886","article-title":"Safety and antitumor activity of acalabrutinib for relapsed\/refractory B-cell malignancies: A Japanese Phase I study","volume":"112","author":"Izutsu","year":"2021","journal-title":"Cancer Sci."},{"issue":"4","key":"10.1016\/j.critrevonc.2023.104085_bib32","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1007\/s12185-020-02929-3","article-title":"Phase I study of duvelisib in Japanese patients with relapsed or refractory lymphoma","volume":"112","author":"Izutsu","year":"2020","journal-title":"Int. J. Hematol."},{"issue":"6","key":"10.1016\/j.critrevonc.2023.104085_bib33","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1002\/ajh.25487","article-title":"Mantle cell lymphoma: 2019 update on the diagnosis, pathogenesis, prognostication, and management","volume":"94","author":"Jain","year":"2019","journal-title":"Am. J. Hematol."},{"issue":"10","key":"10.1016\/j.critrevonc.2023.104085_bib34","doi-asserted-by":"crossref","first-page":"3416","DOI":"10.1172\/JCI61272","article-title":"Molecular pathogenesis of mantle cell lymphoma","volume":"122","author":"Jares","year":"2012","journal-title":"J. Clin. Invest"},{"issue":"3","key":"10.1016\/j.critrevonc.2023.104085_bib35","doi-asserted-by":"crossref","first-page":"e109","DOI":"10.1016\/S2352-3026(18)30018-8","article-title":"Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial","volume":"5","author":"Jerkeman","year":"2018","journal-title":"Lancet Haematol."},{"issue":"1","key":"10.1016\/j.critrevonc.2023.104085_bib36","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s40164-021-00232-3","article-title":"Progress in molecular feature of smoldering mantle cell lymphoma","volume":"10","author":"Jiang","year":"2021","journal-title":"Exp. Hematol. Oncol.,"},{"issue":"1","key":"10.1016\/j.critrevonc.2023.104085_bib37","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1186\/s12943-022-01655-0","article-title":"TIGIT is the central player in T-cell suppression associated with CAR T-cell relapse in mantle cell lymphoma","volume":"21","author":"Jiang","year":"2022","journal-title":"Mol. Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2023.104085_bib38","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/s13045-021-01143-w","article-title":"The antibody drug conjugate VLS-101 targeting ROR1 is effective in CAR T-resistant mantle cell lymphoma","volume":"14","author":"Jiang","year":"2021","journal-title":"J. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2023.104085_bib39","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/s13045-021-01143-w","article-title":"The antibody drug conjugate VLS-101 targeting ROR1 is effective in CAR T-resistant mantle cell lymphoma","volume":"14","author":"Jiang","year":"2021","journal-title":"J. Hematol. Oncol."},{"issue":"10","key":"10.1016\/j.critrevonc.2023.104085_bib40","doi-asserted-by":"crossref","first-page":"2897","DOI":"10.1021\/acschembio.6b00480","article-title":"Battling Btk mutants with noncovalent inhibitors that overcome Cys481 and Thr474 mutations","volume":"11","author":"Johnson","year":"2016","journal-title":"ACS Chem. Biol."},{"issue":"3","key":"10.1016\/j.critrevonc.2023.104085_bib41","doi-asserted-by":"crossref","first-page":"484","DOI":"10.4149\/320_150714N390","article-title":"Gastrointestinal stromal tumors - quantitative detection of the Ki-67, TPX2, TOP2A, and hTERT telomerase subunit mRNA levels to determine proliferation activity and a potential for aggressive biological behavior","volume":"63","author":"Kalfusova","year":"2016","journal-title":"Neoplasma"},{"issue":"1","key":"10.1016\/j.critrevonc.2023.104085_bib42","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1182\/hematology.2022000333","article-title":"What is the role of up-front autologous stem cell transplantation in mantle cell lymphoma?","volume":"2022","author":"Kumar","year":"2022","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"issue":"10","key":"10.1016\/j.critrevonc.2023.104085_bib43","doi-asserted-by":"crossref","first-page":"3439","DOI":"10.1172\/JCI61245","article-title":"Hodgkin lymphoma","volume":"122","author":"K\u00fcppers","year":"2012","journal-title":"J. Clin. Invest."},{"issue":"7","key":"10.1016\/j.critrevonc.2023.104085_bib44","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1182\/blood.2020008727","article-title":"Ibrutinib, obinutuzumab, and venetoclax in relapsed and untreated patients with mantle cell lymphoma: a phase 1\/2 trial","volume":"137","author":"Le Gouill","year":"2021","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.critrevonc.2023.104085_bib45","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1111\/bjh.15107","article-title":"A phase II study of carfilzomib in the treatment of relapsed\/refractory mantle cell lymphoma","volume":"184","author":"Lee","year":"2019","journal-title":"Br. J. Haematol."},{"issue":"17","key":"10.1016\/j.critrevonc.2023.104085_bib46","doi-asserted-by":"crossref","first-page":"4910","DOI":"10.1158\/1078-0432.CCR-21-0464","article-title":"Pharmacologic targeting of Mcl-1 induces mitochondrial dysfunction and apoptosis in B-cell lymphoma cells in a TP53- and BAX-dependent manner","volume":"27","author":"Liu","year":"2021","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.critrevonc.2023.104085_bib47","series-title":"StatPearls","article-title":"Mantle Cell Lymphoma","author":"Lynch","year":"2022"},{"issue":"2","key":"10.1016\/j.critrevonc.2023.104085_bib48","doi-asserted-by":"crossref","first-page":"104","DOI":"10.3324\/haematol.2014.119115","article-title":"The role of targeted treatment in mantle cell lymphoma: is transplant dead or alive?","volume":"101","author":"Martin","year":"2016","journal-title":"Haematologica"},{"issue":"11","key":"10.1016\/j.critrevonc.2023.104085_bib49","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1182\/blood-2018-11-886457","article-title":"A phase 1 trial of ibrutinib plus palbociclib in previously treated mantle cell lymphoma","volume":"133","author":"Martin","year":"2019","journal-title":"Blood"},{"issue":"10277","key":"10.1016\/j.critrevonc.2023.104085_bib50","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/S0140-6736(21)00224-5","article-title":"Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1\/2 study","volume":"397","author":"Mato","year":"2021","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.critrevonc.2023.104085_bib51","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s12185-019-02650-w","article-title":"Combined rituximab, bendamustine, and dexamethasone chemotherapy for relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma: a multicenter phase II study","volume":"110","author":"Matsumoto","year":"2019","journal-title":"Int. J. Hematol."},{"issue":"1","key":"10.1016\/j.critrevonc.2023.104085_bib52","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/bjh.15283","article-title":"Guideline for the management of mantle cell lymphoma","volume":"182","author":"McKay","year":"2018","journal-title":"Br. J. Haematol."},{"issue":"0006\u20134971","key":"10.1016\/j.critrevonc.2023.104085_bib53","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1182\/blood-2020-134872","article-title":"Phase 2 study evaluating the efficacy and safety of parsaclisib in patients with relapsed or refractory mantle cell lymphoma not previously treated with a BTK inhibitor (CITADEL-205","volume":"136","author":"Mehta","year":"2020","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.critrevonc.2023.104085_bib54","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1080\/14656566.2018.1561865","article-title":"Lenalidomide for the treatment of mantle cell lymphoma","volume":"20","author":"Morabito","year":"2019","journal-title":"Expert Opin. Pharmacother."},{"issue":"3","key":"10.1016\/j.critrevonc.2023.104085_bib55","doi-asserted-by":"crossref","first-page":"859","DOI":"10.3324\/haematol.2019.224535","article-title":"Clinical activity of abemaciclib in patients with relapsed or refractory mantle cell lymphoma - a phase II study","volume":"106","author":"Morschhauser","year":"2021","journal-title":"Haematologica"},{"issue":"12","key":"10.1016\/j.critrevonc.2023.104085_bib56","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1182\/blood.2020005289","article-title":"Genomic and epigenomic insights into the origin, pathogenesis, and clinical behavior of mantle cell lymphoma subtypes","volume":"136","author":"Nadeu","year":"2020","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.critrevonc.2023.104085_bib57","doi-asserted-by":"crossref","first-page":"a001008","DOI":"10.1101\/cshperspect.a001008","article-title":"TP53 mutations in human cancers: origins, consequences, and clinical use","volume":"2","author":"Olivier","year":"2010","journal-title":"Cold Spring Harb. Perspect. Biol."},{"issue":"5","key":"10.1016\/j.critrevonc.2023.104085_bib58","first-page":"1490","article-title":"Dose-finding study of ibrutinib and venetoclax in relapsed or refractory mantle cell lymphoma","volume":"6","author":"Portell","year":"2022","journal-title":"Blood Adv."},{"issue":"12","key":"10.1016\/j.critrevonc.2023.104085_bib59","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.neo.2020.09.005","article-title":"ONC201 and imipridones: anti-cancer compounds with clinical efficacy","volume":"22","author":"Prabhu","year":"2020","journal-title":"Neoplasia"},{"issue":"3","key":"10.1016\/j.critrevonc.2023.104085_bib60","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/bjh.14793","article-title":"A multi-centre phase I trial of the PARP inhibitor olaparib in patients with relapsed chronic lymphocytic leukaemia, T-prolymphocytic leukaemia or mantle cell lymphoma","volume":"182","author":"Pratt","year":"2018","journal-title":"Br. J. Haematol."},{"issue":"14","key":"10.1016\/j.critrevonc.2023.104085_bib61","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJM199309303291402","article-title":"A predictive model for aggressive non-Hodgkin's lymphoma","volume":"329","year":"1993","journal-title":"N. Engl. J. Med"},{"issue":"1","key":"10.1016\/j.critrevonc.2023.104085_bib62","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1034\/j.1600-0609.2002.01677.x","article-title":"Ki-67 expression level, histological subtype, and the International Prognostic Index as outcome predictors in mantle cell lymphoma","volume":"69","author":"R\u00e4ty","year":"2002","journal-title":"Eur. J. Haematol."},{"issue":"1","key":"10.1016\/j.critrevonc.2023.104085_bib63","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1470-2045(15)00447-7","article-title":"Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial","volume":"17","author":"Rummel","year":"2016","journal-title":"Lancet Oncol.,"},{"issue":"5","key":"10.1016\/j.critrevonc.2023.104085_bib64","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.clml.2018.12.013","article-title":"Phase 2 study of daratumumab in relapsed\/refractory mantle-cell lymphoma, diffuse large B-cell lymphoma, and follicular lymphoma","volume":"19","author":"Salles","year":"2019","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"22","key":"10.1016\/j.critrevonc.2023.104085_bib65","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14225601","article-title":"Antitumor activity of simvastatin in preclinical models of mantle cell lymphoma","volume":"14","author":"Santos","year":"2022","journal-title":"Cancers"},{"issue":"6","key":"10.1016\/j.critrevonc.2023.104085_bib66","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1080\/10428194.2016.1239259","article-title":"The CDK inhibitor AT7519M in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and mantle cell lymphoma. A phase II study of the Canadian cancer trials group","volume":"58","author":"Seftel","year":"2017","journal-title":"Leuk. Lymphoma"},{"issue":"4","key":"10.1016\/j.critrevonc.2023.104085_bib67","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1007\/s00280-016-3005-y","article-title":"Results of a phase II study of vorinostat in combination with intravenous fludarabine, mitoxantrone, and dexamethasone in patients with relapsed or refractory mantle cell lymphoma: an interim analysis","volume":"77","author":"Shin","year":"2016","journal-title":"Cancer Chemother. Pharmacol.,"},{"issue":"4","key":"10.1016\/j.critrevonc.2023.104085_bib68","doi-asserted-by":"crossref","first-page":"e176","DOI":"10.1016\/S2352-3026(17)30028-5","article-title":"Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials","volume":"4","author":"Smith","year":"2017","journal-title":"Lancet Haematol."},{"issue":"Supplement_1","key":"10.1016\/j.critrevonc.2023.104085_bib69","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-126305","article-title":"Safety and efficacy of orelabrutinib monotherapy in chinese patients with relapsed or refractory mantle cell lymphoma: a multicenter, open-label, phase II study","volume":"134","author":"Song","year":"2019","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.critrevonc.2023.104085_bib70","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/blood-2020-141781","article-title":"Long-term safety and efficacy of orelabrutinib monotherapy in Chinese patients with relapsed or refractory mantle cell lymphoma: a multicenter, open-label, phase II study","volume":"136","author":"Song","year":"2020","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.critrevonc.2023.104085_bib71","doi-asserted-by":"crossref","first-page":"4216","DOI":"10.1158\/1078-0432.CCR-19-3703","article-title":"Treatment of patients with relapsed or refractory mantle-cell lymphoma with zanubrutinib, a selective inhibitor of bruton's tyrosine kinase","volume":"26","author":"Song","year":"2020","journal-title":"Clin. Cancer Res."},{"issue":"8","key":"10.1016\/j.critrevonc.2023.104085_bib72","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1016\/j.mayocp.2015.04.025","article-title":"Non-hodgkin lymphoma: diagnosis and treatment","volume":"90","author":"Stephen","year":"2015","journal-title":"Mayo Clin. Proc."},{"issue":"7","key":"10.1016\/j.critrevonc.2023.104085_bib73","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1038\/s41422-018-0055-1","article-title":"PROTAC-induced BTK degradation as a novel therapy for mutated BTK C481S induced ibrutinib-resistant B-cell malignancies","volume":"28","author":"Sun","year":"2018","journal-title":"Cell Res"},{"issue":"8","key":"10.1016\/j.critrevonc.2023.104085_bib74","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1007\/s00277-020-04159-3","article-title":"Safety and efficacy of temsirolimus in combination with three different immuno-chemotherapy regimens in relapse and refractory mantle cell lymphoma, final results of the T(3) phase IB trial of the LYSA","volume":"99","author":"Tessoulin","year":"2020","journal-title":"Ann. Hematol."},{"issue":"3","key":"10.1016\/j.critrevonc.2023.104085_bib75","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1007\/s12185-018-02577-8","article-title":"Ibrutinib in Japanese patients with relapsed\/refractory B-cell malignancies: Final analysis of Phase I study","volume":"109","author":"Tobinai","year":"2019","journal-title":"Int. J. Hematol."},{"issue":"3","key":"10.1016\/j.critrevonc.2023.104085_bib76","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S1470-2045(15)00559-8","article-title":"Lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase 2, randomised, multicentre trial","volume":"17","author":"Trn\u011bn\u00fd","year":"2016","journal-title":"Lancet Oncol.,"},{"issue":"2","key":"10.1016\/j.critrevonc.2023.104085_bib77","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41408-021-00430-6","article-title":"Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irrespective of prior CD20 monoclonal antibody treatment","volume":"11","author":"van der Horst","year":"2021","journal-title":"Blood Cancer J."},{"issue":"4","key":"10.1016\/j.critrevonc.2023.104085_bib78","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1182\/blood-2015-08-664086","article-title":"A phase 1 clinical trial of the selective BTK inhibitor ONO\/GS-4059 in relapsed and refractory mature B-cell malignancies","volume":"127","author":"Walter","year":"2016","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.critrevonc.2023.104085_bib79","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/bjh.15614","article-title":"Diagnosis of Hodgkin lymphoma in the modern era","volume":"184","author":"Wang","year":"2019","journal-title":"Br. J. Haematol."},{"issue":"14","key":"10.1016\/j.critrevonc.2023.104085_bib80","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.critrevonc.2023.104085_bib81","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1186\/s13045-021-01188-x","article-title":"Concurrent ibrutinib plus venetoclax in relapsed\/refractory mantle cell lymphoma: the safety run-in of the phase 3 SYMPATICO study","volume":"14","author":"Wang","year":"2021","journal-title":"J. Hematol. Oncol."},{"issue":"10121","key":"10.1016\/j.critrevonc.2023.104085_bib82","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S0140-6736(17)33108-2","article-title":"Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial","volume":"391","author":"Wang","year":"2018","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.critrevonc.2023.104085_bib83","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1007\/s00277-021-04619-4","article-title":"Bortezomib in combination with fludarabine plus cyclophosphamide for patients with relapsed or refractory mantle-cell lymphoma: results of the LYM-4003 study","volume":"100","author":"Wang","year":"2021","journal-title":"Ann. Hematol.,"},{"issue":"1","key":"10.1016\/j.critrevonc.2023.104085_bib84","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1182\/asheducation-2013.1.568","article-title":"Transplantation for mantle cell lymphoma: is it the right thing to do?","volume":"2013","author":"Williams","year":"2013","journal-title":"Hematology"},{"issue":"10","key":"10.1016\/j.critrevonc.2023.104085_bib85","doi-asserted-by":"crossref","first-page":"E575","DOI":"10.1002\/ajh.24854","article-title":"Long-term analysis of phase II studies of single-agent lenalidomide in relapsed\/refractory mantle cell lymphoma","volume":"92","author":"Witzig","year":"2017","journal-title":"Am. J. Hematol."},{"issue":"12","key":"10.1016\/j.critrevonc.2023.104085_bib86","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.3324\/haematol.2017.169656","article-title":"Pan-phosphatidylinositol 3-kinase inhibition with buparlisib in patients with relapsed or refractory non-Hodgkin lymphoma","volume":"102","author":"Younes","year":"2017","journal-title":"Haematologica"},{"issue":"11","key":"10.1016\/j.critrevonc.2023.104085_bib87","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.6004\/jnccn.2021.0054","article-title":"NCCN guidelines\u00ae insights: B-Cell lymphomas, version 5.2021","volume":"19","author":"Zelenetz","year":"2021","journal-title":"J. Natl. Compr. Canc. Netw."},{"issue":"1","key":"10.1016\/j.critrevonc.2023.104085_bib88","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.1038\/s41467-021-22872-z","article-title":"Longitudinal single-cell profiling reveals molecular heterogeneity and tumor-immune evolution in refractory mantle cell lymphoma","volume":"12","author":"Zhang","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.critrevonc.2023.104085_bib89","doi-asserted-by":"crossref","first-page":"S396","DOI":"10.1016\/S2152-2650(22)01571-3","article-title":"MCL-319 LP-284 \u2013 a highly potent small molecule targeting mantle cell lymphoma","volume":"22","author":"Zhou","year":"2022","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"1","key":"10.1016\/j.critrevonc.2023.104085_bib90","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1186\/s13045-021-01174-3","article-title":"Zanubrutinib monotherapy in relapsed\/refractory mantle cell lymphoma: a pooled analysis of two clinical trials","volume":"14","author":"Zhou","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.critrevonc.2023.104085_bib91","article-title":"G Protein-Coupled Estrogen Receptor Agonist G-1 Inhibits Mantle Cell Lymphoma Growth in Preclinical Models","volume":"11","author":"Zhou","year":"2021","journal-title":"Front Oncol."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842823001737?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842823001737?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T19:49:05Z","timestamp":1760903345000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842823001737"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":91,"alternative-id":["S1040842823001737"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2023.104085","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combating relapsed and refractory Mantle cell lymphoma with novel therapeutic armamentarium: Recent advances and clinical prospects","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2023.104085","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104085"}}